Njbio India Pharmaceutical Private Limited

Njbio India Pharmaceutical Private Limited - travel and hospitality in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U73100MH2019PTC319319 Incorporated 10 January 2019 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Private Limited Company travel and hospitality DPIIT Startup MSME · Small
Data last updated
Revenue · FY 2025
₹15.2 Cr
▼ 1% YoY
Net profit · FY 2025
₹2.21 Cr
Net margin 14.5%
EBITDA · FY 2025
₹6.61 Cr
EBITDA margin 43.5%
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹16.37 Cr
Issued & subscribed
Satisfied charges
₹8.16 Cr
No open charges
Company age
7 yrs
Est. 2019
Employees · EPFO
38
Provident fund records

About Njbio India Pharmaceutical Private Limited

Data last updated:

Njbio India Pharmaceutical Private Limited is a private limited company based in Mumbai, Maharashtra, India, recognised as a startup by DPIIT. It operates in the consumer and professional services segment of the travel and hospitality sector. It was incorporated on 10 January 2019 and has been in existence for over 7 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U73100MH2019PTC319319. Its GSTIN is 27AARCA7732M1ZZ (Maharashtra).

The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹16.37 Cr. It was formerly known as Amar Chemistry Private Limited. It is led by directors including Rahul Suresh Bagul (Whole-Time Director) and Arpit Pokharna.

Its last annual general meeting (AGM) was held on 22 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1A Ground Floor Ackruti Corporate Park, Mumbai, Maharashtra.

As per the financials filed for FY 2025, the company reported a revenue of ₹15.2 Cr, a decline of 1% compared to the previous year. For the same year it recorded a net profit of ₹2.21 Cr (net margin 14.5%) and EBITDA of ₹6.61 Cr (EBITDA margin 43.5%). Revenue has grown at a compounded annual rate (CAGR) of 38% over three years and 112% over five years.

The company has about 38 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Amar Chemistry. As per MCA filings, the company has satisfied charges of ₹8.16 Cr on record. The company has 3 deals on record (3 rights issues); the latest was in July 2021. The company has 7 MSME Form 1 returns on record between 2020 and 2023, listing 181 overdue payments to 18 micro and small suppliers.

Njbio India Pharmaceutical Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0028267). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website amarchemistry.com.

Company details

CIN U73100MH2019PTC319319
Registration Number 319319
Incorporation Date 10 January 2019
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 22 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
MSME Classification Small
Udyam Registration UDYAM-MH-19-0028267
Key People
Rahul Suresh Bagul Whole-Time Director Arpit Pokharna Director Nareshkumar Fulchand Jain Director

Recognitions & Rankings of Njbio India Pharmaceutical

DPIIT recognised startup Government of India
Startup India
MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-MH-19-0028267

Contact details

Njbio India Pharmaceutical Private Limited's registered office is in Mumbai, Maharashtra. Its website is amarchemistry.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    amarchemistry.com
  • Social Media
  • Registered Address
    G – 1 G – 1A Ground Floor Ackruti Corporate Park Cts No 586 586/1 Lbs Marg Kanjur Village, Bhandup W, Mumbai, Maharashtra, India – 400078
  • Industry
    Travel and Hospitality, Consumer Professional Services

To see the full contact details of Njbio India Pharmaceutical Private Limited, buy the company report.

Comprehensive company report
Njbio India Pharmaceutical Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Njbio India Pharmaceutical operates one associated brand: Amar Chemistry. Each brand links to its own profile.

BrandDescriptionWebsite
Amar Chemistry
Manufactures a range of chemical products, including sodium metabisulfite powder, sodium bisulphites, and sodium sulfite powder.amarchemistry.com

Business activity

The main business activity of Njbio India Pharmaceutical is professional, scientific and technical. In detail, this covers scientific research and development.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
MProfessional, Scientific and TechnicalM5Scientific research and development

To see the full business activity and turnover split of Njbio India Pharmaceutical Private Limited, buy the company report.

Financials of Njbio India Pharmaceutical Private Limited

FY 2025 filings available

Njbio India Pharmaceutical Private Limited reported revenue of ₹15.2 Cr (down 1% YoY) for FY 2025.

Revenue · FY 2025
₹15.2 Cr ▼ 1%
Net profit · FY 2025
₹2.21 Cr margin 14.5%
EBITDA · FY 2025
₹6.61 Cr margin 43.5%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 1%
3 years · compounded
▲ 38%
5 years · compounded
▲ 112%
EBITDA CAGR growth
1 year
▼ 11%
3 years · compounded
▲ 113%
5 years · compounded
▲ 40%

Revenue fell 1% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 112%. EBITDA fell 11% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹6.61 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹2.21 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin43.5%
Net Profit Margin14.5%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Njbio India Pharmaceutical Private Limited, buy the company report.

Board of directors of Njbio India Pharmaceutical Private Limited

Njbio India Pharmaceutical has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Arpit PokharnaDirector01 Sep 20233 Years 2 MonthsCurrent
Rahul Suresh BagulWhole-Time Director16 Dec 20241 Years 10 MonthsCurrent
Nareshkumar Fulchand JainDirector10 Jan 20197 Years 9 MonthsCurrent
View all directors

Auditor

Njbio India Pharmaceutical Private Limited is audited by Sheth Doshi & Associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Sheth Doshi & AssociatesFY 2023110052W

Shareholding

The shareholding of Njbio India Pharmaceutical Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023FY 2022FY 2021FY 2020FY 2019
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Njbio India Pharmaceutical Private Limited, buy the company report.

Charges & borrowings

Open charges
None
Satisfied charges
₹8.16 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹8.16 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
20 Aug 2019100288656Hdfc Bank Limited₹8.16 CrSatisfied

To see the full charge records of Njbio India Pharmaceutical Private Limited, buy the company report.

Total charge records: 1 View all charges

Deals & funding

Njbio India Pharmaceutical Private Limited has 3 deals on record (3 rights issues); the latest was in July 2021.

Total deals
3
Rights issues
3

Deals on record (3 of 3)

WhenDealAmountParties
Jul 2021Rights issue₹2.49 CrInvestors: 3 individuals
Dec 2020Rights issue₹2.52 CrInvestors: 2 individuals
Mar 2019Rights issue₹3.98 CrInvestors: 4 individuals

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Njbio India Pharmaceutical Private Limited has 7 MSME Form 1 returns on record between 2020 and 2023, listing 181 overdue payments to 18 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 18)

SupplierAmount dueDue sinceReported on
Spark Scientific Private Limited
BLD Pharmatech (India) Private Limited
an individual supplier
National Chemical Co
an individual supplier

To see the full MSME payment records of Njbio India Pharmaceutical Private Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Njbio India Pharmaceutical Private Limited has a workforce of 38 employees on its EPFO records as of Apr 05, 2024, across 1 active EPFO establishment.

Employee count
38
Active EPFO establishments
1
Employee growth
26.67%

GST

Njbio India Pharmaceutical has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AARCA7732M1ZZMaharashtraActive31 Jan 2019

To see the full GST registrations and return filing status of Njbio India Pharmaceutical Private Limited, buy the company report.

Recent activity

Njbio India Pharmaceutical Private Limited has 7 board changes on record since 2019: 3 appointments and 4 cessations. The latest: Rahul Suresh Bagul ceased to be Additional Director on 23 Apr 2025.

AGM
Njbio India Pharmaceutical Private Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records.
Ceased
Rahul Suresh Bagul ceased to be Additional Director.
Filing
Njbio India Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Appointed
Rahul Suresh Bagul was appointed as Whole-Time Director.
Ceased
Arpit Pokharna ceased to be Additional Director.
Appointed
Arpit Pokharna was appointed as Director.
Ceased
Vishal Naresh Shah ceased to be Managing Director.
Charges
A charge registered on 20 Aug 2019 via Charge ID 100288656 with Hdfc Bank Limited was fully satisfied on 23 May 2023.
Charges
A charge with Hdfc Bank Limited of Rs. 8.16 Cr registered on 20 Aug 2019 with Charge ID 100288656 was modified on 02 Feb 2021.
Ceased
Mansi Vishal Shah ceased to be Additional Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 8.16 Cr with Charge ID 100288656 was registered on 20 Aug 2019.
Appointed
Nareshkumar Fulchand Jain was appointed as Director.

1 earlier event is in the company report.

Frequently asked questions

Njbio India Pharmaceutical is an active private limited company based in Mumbai, Maharashtra, India. The company works in consumer professional services, within the travel and hospitality industry. It was incorporated on 10 January 2019 (7+ years old) and is registered under CIN U73100MH2019PTC319319.

Njbio India Pharmaceutical has 3 current directors:

The latest financial statements of Njbio India Pharmaceutical on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 August 2025. Year-wise statements from FY 2019 are in the company report.

The GSTIN of Njbio India Pharmaceutical is 27AARCA7732M1ZZ, registered in Maharashtra.

The CIN (Corporate Identification Number) of Njbio India Pharmaceutical is U73100MH2019PTC319319. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Njbio India Pharmaceutical was incorporated on 10 January 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.

Njbio India Pharmaceutical has 3 deals on record (3 rights issues); the latest was in July 2021.

Rahul Suresh Bagul ceased to be Additional Director on 23 Apr 2025. Rahul Suresh Bagul was appointed as Whole-Time Director on 16 Dec 2024. Arpit Pokharna ceased to be Additional Director on 28 Sep 2023. Njbio India Pharmaceutical has 7 board changes on record in total.

Yes, Njbio India Pharmaceutical is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).

Yes, Njbio India Pharmaceutical is registered as a small enterprise under Udyam registration (number: UDYAM-MH-19-0028267).

Njbio India Pharmaceutical has 7 MSME Form 1 returns on record between 2020 and 2023, listing 181 overdue payments to 18 micro and small suppliers. The latest return was filed on 08 Dec 2023.